Skip to main content

Waters Competitors

$315.48
+11.84 (+3.90 %)
(As of 05/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$305.32
$317.54
50-Day Range
$269.05
$317.63
52-Week Range
$171.38
$320.39
Volume416,661 shs
Average Volume373,921 shs
Market Capitalization$19.47 billion
P/E Ratio39.29
Dividend YieldN/A
Beta0.97

Competitors

Waters (NYSE:WAT) Vs. TMO, ILMN, A, MTD, BIO, and CRL

Should you be buying WAT stock or one of its competitors? Companies in the sub-industry of "life sciences tools & services" are considered alternatives and competitors to Waters, including Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories (BIO), and Charles River Laboratories International (CRL).

Thermo Fisher Scientific (NYSE:TMO) and Waters (NYSE:WAT) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings and valuation.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Thermo Fisher Scientific and Waters, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Thermo Fisher Scientific021802.90
Waters37101.82

Thermo Fisher Scientific presently has a consensus target price of $536.8947, indicating a potential upside of 17.50%. Waters has a consensus target price of $251.25, indicating a potential downside of 20.36%. Given Thermo Fisher Scientific's stronger consensus rating and higher probable upside, research analysts plainly believe Thermo Fisher Scientific is more favorable than Waters.

Risk and Volatility

Thermo Fisher Scientific has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Waters has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500.

Insider & Institutional Ownership

87.2% of Thermo Fisher Scientific shares are held by institutional investors. Comparatively, 91.8% of Waters shares are held by institutional investors. 0.4% of Thermo Fisher Scientific shares are held by insiders. Comparatively, 1.5% of Waters shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Thermo Fisher Scientific and Waters' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Thermo Fisher Scientific17.12%21.35%10.55%
Waters22.61%-349.31%21.11%

Valuation and Earnings

This table compares Thermo Fisher Scientific and Waters' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Thermo Fisher Scientific$25.54 billion7.03$3.70 billion$12.3537.00
Waters$2.41 billion8.09$592.20 million$8.9935.09

Thermo Fisher Scientific has higher revenue and earnings than Waters. Waters is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Illumina (NASDAQ:ILMN) and Waters (NYSE:WAT) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, analyst recommendations, risk, institutional ownership, profitability and earnings.

Profitability

This table compares Illumina and Waters' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Illumina19.70%15.93%10.09%
Waters22.61%-349.31%21.11%

Volatility & Risk

Illumina has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500. Comparatively, Waters has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Illumina and Waters, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Illumina47602.12
Waters37101.82

Illumina currently has a consensus target price of $374.50, indicating a potential upside of 0.28%. Waters has a consensus target price of $251.25, indicating a potential downside of 20.36%. Given Illumina's stronger consensus rating and higher possible upside, equities research analysts clearly believe Illumina is more favorable than Waters.

Valuation and Earnings

This table compares Illumina and Waters' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Illumina$3.54 billion15.39$1.00 billion$6.5756.84
Waters$2.41 billion8.09$592.20 million$8.9935.09

Illumina has higher revenue and earnings than Waters. Waters is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

90.0% of Illumina shares are held by institutional investors. Comparatively, 91.8% of Waters shares are held by institutional investors. 0.4% of Illumina shares are held by company insiders. Comparatively, 1.5% of Waters shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Illumina beats Waters on 9 of the 14 factors compared between the two stocks.

Agilent Technologies (NYSE:A) and Waters (NYSE:WAT) are both large-cap computer and technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, institutional ownership, risk, dividends and earnings.

Profitability

This table compares Agilent Technologies and Waters' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Agilent Technologies13.47%21.02%10.73%
Waters22.61%-349.31%21.11%

Insider & Institutional Ownership

91.8% of Waters shares are owned by institutional investors. 1.5% of Waters shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Agilent Technologies and Waters' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agilent Technologies$5.34 billion7.42$719 million$3.2839.64
Waters$2.41 billion8.09$592.20 million$8.9935.09

Agilent Technologies has higher revenue and earnings than Waters. Waters is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Agilent Technologies has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Waters has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Agilent Technologies and Waters, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Agilent Technologies052002.80
Waters37101.82

Agilent Technologies currently has a consensus target price of $108.1850, suggesting a potential downside of 16.79%. Waters has a consensus target price of $251.25, suggesting a potential downside of 20.36%. Given Agilent Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Agilent Technologies is more favorable than Waters.

Summary

Agilent Technologies beats Waters on 8 of the 14 factors compared between the two stocks.

Mettler-Toledo International (NYSE:MTD) and Waters (NYSE:WAT) are both large-cap computer and technology companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Volatility and Risk

Mettler-Toledo International has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, Waters has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500.

Profitability

This table compares Mettler-Toledo International and Waters' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mettler-Toledo International19.36%144.89%21.11%
Waters22.61%-349.31%21.11%

Institutional & Insider Ownership

93.2% of Mettler-Toledo International shares are held by institutional investors. Comparatively, 91.8% of Waters shares are held by institutional investors. 3.2% of Mettler-Toledo International shares are held by company insiders. Comparatively, 1.5% of Waters shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Mettler-Toledo International and Waters' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mettler-Toledo International$3.01 billion9.70$561.11 million$22.7755.06
Waters$2.41 billion8.09$592.20 million$8.9935.09

Waters has lower revenue, but higher earnings than Mettler-Toledo International. Waters is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Mettler-Toledo International and Waters, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mettler-Toledo International23101.83
Waters37101.82

Mettler-Toledo International currently has a consensus target price of $1,048.3333, suggesting a potential downside of 16.38%. Waters has a consensus target price of $251.25, suggesting a potential downside of 20.36%. Given Mettler-Toledo International's stronger consensus rating and higher possible upside, equities research analysts plainly believe Mettler-Toledo International is more favorable than Waters.

Summary

Mettler-Toledo International beats Waters on 10 of the 12 factors compared between the two stocks.

Bio-Rad Laboratories (NYSE:BIO) and Waters (NYSE:WAT) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Institutional and Insider Ownership

63.0% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 91.8% of Waters shares are owned by institutional investors. 27.5% of Bio-Rad Laboratories shares are owned by insiders. Comparatively, 1.5% of Waters shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and price targets for Bio-Rad Laboratories and Waters, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bio-Rad Laboratories00303.00
Waters37101.82

Bio-Rad Laboratories currently has a consensus target price of $700.00, indicating a potential upside of 18.45%. Waters has a consensus target price of $251.25, indicating a potential downside of 20.36%. Given Bio-Rad Laboratories' stronger consensus rating and higher probable upside, research analysts plainly believe Bio-Rad Laboratories is more favorable than Waters.

Profitability

This table compares Bio-Rad Laboratories and Waters' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bio-Rad Laboratories147.91%3.77%2.74%
Waters22.61%-349.31%21.11%

Volatility and Risk

Bio-Rad Laboratories has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Waters has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500.

Valuation & Earnings

This table compares Bio-Rad Laboratories and Waters' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.31 billion7.61$1.76 billion$7.0683.71
Waters$2.41 billion8.09$592.20 million$8.9935.09

Bio-Rad Laboratories has higher earnings, but lower revenue than Waters. Waters is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Charles River Laboratories International (NYSE:CRL) and Waters (NYSE:WAT) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, profitability, institutional ownership and earnings.

Volatility & Risk

Charles River Laboratories International has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500. Comparatively, Waters has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500.

Institutional and Insider Ownership

92.3% of Charles River Laboratories International shares are held by institutional investors. Comparatively, 91.8% of Waters shares are held by institutional investors. 1.9% of Charles River Laboratories International shares are held by company insiders. Comparatively, 1.5% of Waters shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Charles River Laboratories International and Waters' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Charles River Laboratories International10.68%22.41%7.66%
Waters22.61%-349.31%21.11%

Analyst Ratings

This is a summary of recent recommendations and price targets for Charles River Laboratories International and Waters, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Charles River Laboratories International03902.75
Waters37101.82

Charles River Laboratories International currently has a consensus price target of $286.4167, indicating a potential downside of 10.78%. Waters has a consensus price target of $251.25, indicating a potential downside of 20.36%. Given Charles River Laboratories International's stronger consensus rating and higher possible upside, analysts clearly believe Charles River Laboratories International is more favorable than Waters.

Earnings & Valuation

This table compares Charles River Laboratories International and Waters' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Charles River Laboratories International$2.62 billion6.15$252.02 million$6.7347.70
Waters$2.41 billion8.09$592.20 million$8.9935.09

Waters has lower revenue, but higher earnings than Charles River Laboratories International. Waters is trading at a lower price-to-earnings ratio than Charles River Laboratories International, indicating that it is currently the more affordable of the two stocks.

Summary

Charles River Laboratories International beats Waters on 9 of the 14 factors compared between the two stocks.


Waters Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Thermo Fisher Scientific logo
TMO
Thermo Fisher Scientific
2.3$456.92+0.5%$179.58 billion$25.54 billion37.45Insider Selling
Analyst Revision
Illumina logo
ILMN
Illumina
1.6$373.45+0.2%$54.52 billion$3.54 billion86.65
Agilent Technologies logo
A
Agilent Technologies
1.8$130.02+1.1%$39.62 billion$5.34 billion56.53Analyst Upgrade
Mettler-Toledo International logo
MTD
Mettler-Toledo International
1.3$1,253.64+1.0%$29.17 billion$3.01 billion52.74Insider Selling
News Coverage
Bio-Rad Laboratories logo
BIO
Bio-Rad Laboratories
1.5$590.97+1.2%$17.59 billion$2.31 billion5.06
Charles River Laboratories International logo
CRL
Charles River Laboratories International
1.3$321.01+1.3%$16.13 billion$2.62 billion53.50Insider Selling
PerkinElmer logo
PKI
PerkinElmer
1.9$141.27+2.4%$15.83 billion$2.88 billion38.39
Bio-Techne logo
TECH
Bio-Techne
1.8$396.66+3.1%$15.43 billion$738.69 million63.47
Bruker logo
BRKR
Bruker
1.8$67.53+1.6%$10.23 billion$2.07 billion66.21High Trading Volume
Pacific Biosciences of California logo
PACB
Pacific Biosciences of California
1.6$22.30+2.8%$4.42 billion$90.89 million-79.64
Luminex logo
LMNX
Luminex
1.5$36.65+0.1%$1.73 billion$334.64 million93.98
Fluidigm logo
FLDM
Fluidigm
1.8$5.14+0.8%$385.31 million$117.24 million-7.67Analyst Report
Harvard Bioscience logo
HBIO
Harvard Bioscience
1.8$6.92+0.4%$276.50 million$116.18 million-38.44
aTyr Pharma logo
LIFE
aTyr Pharma
1.5$3.62+6.4%$57.96 million$420,000.00-1.36Earnings Announcement
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.